Posted by Michael Wonder on 05 May 2022
ICER to assess gene therapies for haemophilia A and B
5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public comment until 25 May 2022.
The ICER announced today that it will assess the comparative clinical effectiveness and value of etranacogene dezaparvovec (CSL Behring) for haemophilia B.
ICER will also update our previous haemophilia A assessment on valoctocogene roxaparvovec (Roctavian; BioMarin).
